Fig. 1: DARS-AS1 is characterized as an oncogenic lncRNA.
a Schematic representation of screening using the CRISPRi system. b Enrichment of sgRNAs after screening. The horizontal dotted lines represent log2(Fold change) = ±0.58. The vertical dotted line represents p value = 0.05. Black dots are non-targeting sgRNAs (marked as NC). Red dots are sgRNAs targeting DARS-AS1. Blue dots are sgRNAs targeting LINC00205, a previously reported oncogenic lncRNA. Fold change = (normalized reads day 17)/(normalized reads day 0). c Knockdown DARS-AS1 by sgRNAs inhibits cell growth. Error bars represent ±SD in triplicate experiments. *p ≤ 0.05, **p ≤ 0.01, by two-tailed Student’s t test. d Expression of DARS-AS1 in tumors (TCGA datasets). e–m Expression of DARS-AS1 in paired normal and tumor samples from BLCA, KIRC, PRAD, LUSC, UCEC, LUAD, LIHC, KIRP and COAD patients, respectively (TCGA datasets). p values were obtained by paired two-tailed Student’s t test.
